Labcorp Holdings is a diagnostic & research company located in North Carolina, United States, which is part of the Healthcare sector, and is traded under the ticker LH on the NYSE exchange.
Labcorp Holdings stock last closed at $212.22, down 2.26% from the previous day, and has increased 4.51% in one year. It has overperformed other stocks in the Diagnostics & Research industry by 0.35 percentage points. Labcorp Holdings stock is currently +10.55% from its 52-week low of $191.97, and -17.93% from its 52-week high of $258.59.
At the moment, there are 83.7M shares of LH outstanding. The market capitalization of LH is $17.76B. In the last 24 hours, 740,816 LH shares were traded.
You will need an online brokerage account in order to access the NYSE market and buy LH stock.
In our opinion, eToro is the best place to buy stocks. eToro gives you:
Get $10 towards your stock purchase by signing up for an account with eToro now. This offer is only for US users.
Open eToro AccountNow that you've chosen the best brokerage, the next step is to fill out some personal info so you are able to invest in LH stock today.
Now that you have filled out your info on the best stock trading app for beginners, your next step is to transfer the money for your investment:
Watch the walkthrough below if you need help depositing money into your investment account.
After you have identified the best place to buy Labcorp Holdings stock, it's important to analyze their stock before you invest, so you truly wrap your head around the risk as well as the upside.
WallStreetZen was built to help average investors perform better fundamental analysis in less time.
You can view all of the due diligence checks on LH's stock page.
You can use a variety of different financial metrics, analyses, models, and charts to gauge LH's intrinsic value.
Using relative valuations measures:
You can do more valuation analysis on LH's stock here.
Out of 11 Wall Street analysts who give ratings on LH, the consensus analyst rating on LH is a Strong Buy
Please keep in mind that analyst ratings are not stock recommendations, nor are they investment advice.
Tycho Peterson, a top 15% analyst from Jefferies maintains LH with a strong buy rating and raises their LH price target from $275.00 to $290.00, on Feb 6, 2025.
Jefferies's Tycho Peterson raised their price target on Labcorp Holdings (NYSE: LH) by 5.5% from $275 to $290 on 2025/02/07. The analyst maintained their Strong Buy rating on the stock.
Labcorp Holdings reported its Q4 and FY 2024 earnings on 2025/02/06.
Quarterly EPS and revenue beat estimates, while management's FY 2025 guidance was above on the top-line and EPS bracketed expectations, Peterson told readers.
Given that the company's diagnostics division offers protection from "broader healthcare noise," the analyst said the stock is a good buy.
Labcorp Holdings reported:
For Q4 2024:
For FY 2024:
For FY 2025, management guided:
Chairman & CEO Adam Schechter commented: "In 2024, Labcorp delivered exceptional results driven by both organic and inorganic growth.
"We announced 10 transactions to further establish our position as a trusted partner to hospitals, health systems, and regional/local laboratories.
“Additionally, we strengthened our presence in key high-growth areas including oncology, women's health, neurology, and autoimmune disease.
“In 2025, we are positioned to deliver strong growth and margin expansion across both Diagnostics Laboratories and Biopharma Laboratory Services, while we improve health and improve lives of patients around the world."
Kevin Caliendo, a top 15% analyst from UBS maintains LH with a strong buy rating and lowers their LH price target from $293.00 to $286.00, on Jan 28, 2025.
Elizabeth Anderson, a bottom 9% analyst from Evercore ISI Group upgrades LH to a buy rating and raises their LH price target from $260.00 to $265.00, on Jan 7, 2025.
Ricky Goldwasser, a top 6% analyst from Morgan Stanley maintains LH with a strong buy rating and raises their LH price target from $260.00 to $270.00, on Dec 17, 2024.
Derik De Bruin, a top 9% analyst from Bank of America maintains LH with a strong buy rating and raises their LH price target from $262.00 to $271.00, on Dec 13, 2024.
You can dive deeper into what analysts are projecting on the Labcorp Holdings stock forecast page.
Last year, LH earnings were $746.00M. Over the past 5 year, LH's earnings have gone up by 1.09% per year. This was slower than the Diagnostics & Research industry average of 8.57%.
Last year, LH revenue was $13.01B. In the past five year, LH's revenue has increased by 2.4% per year. This was slower than the Diagnostics & Research industry average of 9.93%.
Dig into LH's earnings and revenue performance here.
Over the past year, executives and large shareholders at LH have sold more shares than they have bought.
Megan D. Bailey, EVP Pres Central Labs Intl of LH, was the latest LH insider to sell. They sold $359,676.90 worth of LH stock on Apr 1, 2025.
Learn more about who owns LH stock here.
Labcorp Holdings pays a dividend of 0.68%, compared to the Diagnostics & Research industry's average dividend yield of 0.64%. If you owned $1,000 of LH stock, you would have received $6.79 last year.
Labcorp Holdings dividend payments have not consistently grown over the past decade but have remained stable.
Get more info about Labcorp Holdings dividend yield and history here.
One of the reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to see what other investors have to say.
There are two main types of orders:
Press the Open button and your broker will execute the order.
If you want additional info about buying stocks on eToro, watch the how to video below:
Now that you own some shares in LH, you'll want to stay up-to-date on your stock purchase.
Start a watchlist to get notified of important updates regarding your LH stock.
To summarize, here are the 6 steps to buy stock in Labcorp Holdings:
If you need a brokerage account, eToro is our favorite venue.
Get Started with eToro TodayIf you want to watch your investment in Labcorp Holdings, click below.